SheMed’s Weight Loss Programme Gains Momentum as UK Women Seek Safer, Science-Backed Solutions

By 
Dr Amit Kumar Singh
 on 
Feb 20, 2025
 • 
5
 min read

A new weight loss programme is gaining significant traction across the UK, drawing more than 16,000 women in just two months. SheMed, a digital health provider, is reshaping how women approach weight management by integrating scientific precision with a patient-first philosophy.

Unlike conventional dieting plans, SheMed’s approach is designed specifically for women’s unique metabolic and hormonal profiles. The programme, which includes a GLP-1-based medical intervention, aims to promote sustainable weight loss without extreme dieting or unrealistic exercise regimens.

“We understand that women’s bodies work differently, and our programme is tailored to reflect that,” said Olivia Ferro, co-founder & CEO of SheMed. “This isn’t just about weight loss—it’s about long-term health, confidence, and a fundamentally different approach to well-being.”

A Medical-Grade Approach to Weight Loss

SheMed differentiates itself by offering a medically supervised weight loss programme that combines prescription GLP-1 medications with private GP oversight. The programme’s core principles include:

  • Personalised Treatment Plans – Tailored weight loss strategies based on individual metabolic needs.
  • Clinical Oversight – Direct access to private GPs for medical supervision.
  • A Supportive Community – A peer network providing motivation and shared experiences.
  • Sustainable Health Outcomes – A focus on long-term success rather than quick fixes.

Uncovering Hidden Health Risks

As part of its commitment to responsible prescribing, SheMed introduced a mandatory blood test requirement for all patients before administering GLP-1 medications. The results of this initiative were striking: 99% of applicants exhibited health conditions, including high cholesterol, fatty liver, and early-stage diabetes.

Initially launched as a clinical study, the blood test requirement has now been made permanent. “This initiative has fundamentally changed how we assess weight loss patients,” said Chloe Ferro, SheMed’s co-founder and Chief Growth Officer. “Many women seeking weight loss treatment had underlying health conditions they weren’t aware of. Early detection is key to improving long-term health outcomes.”

The General Pharmaceutical Council (GPhC) has recently tightened regulations around online prescriptions for obesity medications. SheMed’s rigorous screening process places it ahead of industry standards, ensuring that only patients meeting strict medical criteria receive treatment. The company’s fixed pricing model—£159 every four weeks, with no cost increase as medication doses adjust—further differentiates it in a market where pricing structures often fluctuate unpredictably.

Regulatory Scrutiny and Industry Implications

SheMed’s stringent protocols come at a time of heightened regulatory scrutiny over the distribution of GLP-1 medications in the UK. With the rise in popularity of these drugs, regulators have moved to curb inappropriate prescribing practices. Unlike some providers, SheMed does not base eligibility solely on weight or BMI. Instead, its screening process considers broader health indicators, ensuring treatment aligns with patient safety guidelines.

“We’re not just another online pharmacy dispensing GLP-1s,” said Olivia Ferro. “We’re setting new standards for what responsible prescribing should look like.”

As the UK continues to grapple with rising obesity rates and evolving treatment protocols, SheMed’s approach offers a glimpse into the future of medically integrated digital health solutions. With a growing patient base and increasing regulatory backing for stricter prescribing practices, the company is positioned as a leader in the next phase of weight loss care.

For more information, visit www.shemed.co.uk

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.